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Abstract
Background: Previous studies have demonstrated an association between DNA methylation-based measures of
accelerated ageing and age-related health outcomes and mortality. As a disease closely associated with advancing
age, we hypothesized that DNA methylation-based measures of accelerated ageing might be associated with risk
for dementia. This study therefore aimed to examine the association between four recognised measures of age
acceleration and subsequent dementia.
Methods: Study subjects (n = 488) were members of the Lothian Birth Cohort 1921. Dementia case ascertainment
used data from death certificates, electronic hospital records, and clinical reviews. Venous blood samples were
taken at baseline, at age 79 years. DNA methylation and measures of epigenetic age were calculated in accordance
with Horvath’s epigenetic clock tutorial, using the online calculator (https://dnamage.genetics.ucla.edu/). From these
values, four measures of accelerated ageing were calculated: extrinsic epigenetic age acceleration (EEAA), intrinsic
epigenetic age acceleration (IEAA), AgeAccelPheno and AgeAccelGrim. Competing risk regression models – with
death as a competing risk – were performed to examine the association between each measure of accelerated
ageing and incident dementia. APOE ɛ4 status, sex, age, smoking status, history of cardiovascular disease,
cerebrovascular disease, hypertension, and diabetes were included as covariates.
Results: None of the multivariate models revealed a positive association between increased epigenetic age
acceleration and dementia risk. Across all included models, never-smoking increased risk for dementia (HR 1.69
[1.06, 2.71], p = 0.03), and having no APOE ɛ4 alleles reduced risk for dementia (HR 0.44 [0.29, 0.67], p < 0.001).
Conclusions: The present study did not demonstrate any consistent association between DNA methylation-based
measures of accelerated ageing and dementia in subjects aged over 79 years. Further, larger studies – including
separate analyses of dementia subtypes – are required to further investigate the potential association between DNA
methylation-based measures of accelerated ageing and dementia.
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Background
As the global population ages, diseases closely associated
with advancing age are projected to increase in number as
a result. Dementia is one such disease, the most common
cause for which is Alzheimer’s disease (AD). As the num-
ber of dementia cases increases, so will the economic and
social care requirements [1]. Managing the impact of
dementia will therefore pose a significant public health
challenge. Gaining a comprehensive understanding of the
risk factors for dementia is a vital step in addressing this
challenge.
It is recognised that both genetic and environmental fac-
tors contribute to the development of dementia. There is,
however, considerable variability in the risk that one will
develop the disease. It is thought therefore, that the aeti-
ology is likely to be a complex interaction between genetic
and environmental factors. Epigenetics could be considered
to be a bridge between genes and the environment, with
exposure to environmental factors giving rise to alterations
in gene expression, via epigenetic mechanisms [2]. Unsur-
prisingly, the study of epigenetics is an area of considerable
research interest and it may prove to be important in un-
derstanding dementia risk.
Older age is widely recognised to be the most signifi-
cant risk factor for dementia. However, it is clear that
some individuals age more successfully than others, in
that, for some, advancing age has less effect on physical
robustness, health (and disease) status and cognitive
function [3, 4]. The explanation for individual differ-
ences in the effect of ageing is also likely to be multifac-
torial, with genetic, lifestyle and health factors all playing
a role [3]. It has been suggested that each individual has
a biological or physiological age that may differ from
chronological age and is the result of such factors. Fur-
thermore, studies have shown that each individual may
have a series of biological ages, depending on the bio-
marker used to estimate age, suggesting that the biological
ageing process may not just vary between individuals, but
also within each individual [5].
Patterns of a specific epigenetic modification within the
DNA sequence – DNA methylation – have been used in
previous studies to calculate estimates of biological age.
DNA methylation is one of the most frequently-studied
epigenetic marks and occurs with the addition of a methyl
group to the DNA molecule, typically at a cytosine nucleo-
tide that precedes a guanine nucleotide – CpG sites [2].
Such estimates of age are typically referred to as the
‘epigenetic age’ or ‘DNAm (DNA methylation) age’ and are
suggested to reflect both an individual’s biological age and
their susceptibility to age-related health outcomes [6].
DNA methylation-based estimates of age have been shown
to be consistent across biological sample types, including
blood and various tissues [6]. Whereas epigenetic age has
been shown to correlate highly with chronological age,
significant discrepancies between the two are noted at the
individual level [6]. Studies comparing chronological age
with epigenetic age found that there was an increased risk
of all-cause mortality for those exhibiting accelerated
ageing – i.e. those who had higher epigenetic age than
chronological age – after adjusting for related genetic,
health and lifestyle factors [6, 7]. Furthermore, the off-
spring of persons surviving to 105–109 years of age have
been shown to have a lower epigenetic age than age-
matched controls [8]. A number of suggested risk factors
for dementia have also been shown to be associated with
greater age acceleration; poorer physical fitness, lower
cognitive ability, lower socioeconomic status, greater body
mass index, higher total cholesterol to high-density lipo-
protein cholesterol ratios, hypertension and smoking
(greater pack-years) have all been shown to be associated
with greater age acceleration (calculated using DNA
methylation-based measures) [9, 10]. Based on these previ-
ous findings, we hypothesized that measures of accelerated
biological ageing based on DNA methylation would be a
valuable predictor of dementia risk.
This study would consider four recognised DNA
methylation-based measures of accelerated ageing: the
two first-generation measures of age acceleration – in-
trinsic epigenetic age acceleration (IEAA) and extrinsic
epigenetic age acceleration (EEAA) – and the two novel
estimates of age acceleration – AgeAccelPheno (based
on PhenoAge) and AgeAccelGrim (based on GrimAge).
The rationale for including the older measures was that
these have been the most consistently reported in the lit-
erature and there is therefore more evidentiary basis that
these measures were valid and appropriate for inclusion
in our study. The novel measures were included on the
basis that these have been shown to be more accurate
predictors of mortality, time-to-death and other morbid-
ities than the earlier measures [11, 12].
The earlier measures – IEAA and EEAA – were based on
methods for estimating epigenetic age described by Hor-
vath [13] and Hannum et al. [14], respectively, in 2013 [6].
Horvath’s epigenetic age estimate is based on DNA methy-
lation at 353 CpGs, while Hannum’s epigenetic age esti-
mate is based on DNA methylation at 71 CpGs. Both age
acceleration measures compare epigenetic age estimates
with chronological age in order to define age acceleration.
The age acceleration measures also differ however, in that
IEAA is independent of changes in blood cell composition,
whereas EEAA incorporates age-related changes in blood
cell composition [6]. Whereas the epigenetic age estimates
produced using these measures have demonstrated statisti-
cally significant associations with age-related conditions,
the effect sizes seen have been relatively small [11].
Levine et al. proposed that a new, more successful
DNA methylation-based measure of epigenetic age may
be developed by using “phenotypic age” as a reference,
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rather than chronological age [11]. So-called “phenotypic
aging measures” are based on clinical biomarkers (albumin,
creatinine, serum glucose, C-reactive protein, lymphocyte
percent, mean cell volume, red cell distribution width, alka-
line phosphatase, white blood cell count) and age, and had
previously been shown to be associated with differences in
risk for mortality, physical and cognitive function, facial
ageing and life expectancy [11]. In 2018, Levine et al. pub-
lished the novel measure for epigenetic age, produced by
regressing a phenotypic measure of mortality risk on CpGs:
DNAm PhenoAge [11].
More recently, Lu et al. published another novel measure
of epigenetic age, termed DNAm GrimAge [12]. In a two-
step process, the authors began by identifying DNA
methylation-based biomarkers of mortality and morbidity
including several plasma proteins and smoking pack-years;
time-to death was then regressed onto these biomarkers,
producing a single composite biomarker of lifespan: DNAm
GrimAge [12]. By adjusting the measure for chronological
age, the authors produced a measure of age acceleration:
AgeAccelGrim [12]. Each of the four measures are in units
of year.
Given the differences in how each measure arrives at a
calculation of epigenetic age acceleration, and the differ-
ences between measures in the accuracy of prediction
for other outcomes shown in previous studies, one
would not necessarily expect our results to be consistent
between age acceleration measures. Because the novel
methods have been shown to be more accurate predic-
tors of morbidity and mortality in previous studies, we
might expect that these measures would be more accur-
ate in predicting incident dementia.
In summary, we explore the associations between four
DNA methylation-based measures of accelerated ageing
and n = 109 cases of incident dementia from a cohort of
n = 488 individuals, who were healthy when recruited at
age 79 years, and followed-up for approximately 16 years.
Given the known association between accelerated ageing
and mortality, we recognised the potential for death to
affect our findings. Death is therefore considered as a
competing risk in our analyses.
Methods
Participants
Participants were members of the Lothian Birth Cohort
1921 (LBC1921), recruited from 1999, with baseline test-
ing at mean age 79 years. The cohort has been described
in detail within the literature and an overview will be
provided here [15, 16]. All participants were born in
1921, and most had taken part in a general intelligence
test at age 11 years – the Scottish Mental Survey 1932
(SMS1932) [17, 18]. The survey was completed within
Scottish schools and used a validated test of intelligence.
SMS1932 participants were recruited for follow-up in
later life, with the aim of investigating the possible deter-
minants of non-pathological cognitive ageing [19]. Five-
hundred and fifty relatively healthy and independently
living participants, residing mostly in and around the
Lothian area of Scotland, enrolled in the study and
attended baseline testing. Surviving participants who
remained in the study were re-tested at four subsequent
test waves; at approximately 83, 87, 90 and 92 years of
age [16]. Test waves used questionnaires and in-person
testing and collected medical, physiological, genetic,
cognitive, psychological and socio-demographic data.
Information regarding participants who had died was
provided at regular intervals by the General Registrar’s
Office, Scotland.
Only those participants scoring 24 or higher on the
Folstein Mini Mental State Examination (MMSE) [20] at
baseline (n = 539) were included in the present study.
Similarly, those reporting a history of dementia at base-
line (n = 2) were not included. These exclusions were
made in order to minimise the possibility that we were
including prevalent cases of dementia in our analyses.
Without such exclusions there is the possibility that we
could falsely identify an association between epigenetic
age acceleration and risk for incident dementia – when
we were in fact identifying an association between epi-
genetic age acceleration and existing dementia. Ethical
approval for the study was provided by the Lothian Re-
search Ethics Committee (test waves 1–3) and the Scotland
A Research Ethics Committee (test waves 4–5). From wave
4 onwards, participants were asked to provide consent for
data linkage and access to health records.
Measures of DNA methylation
Blood samples extracted at wave 1 (mean age 79) were
used in the present study. DNA was extracted from
whole blood samples at MRC Technology, Western
General Hospital, Edinburgh, UK. Methylation typing
was performed at the Welcome Trust Clinical Research
Facility, Western General Hospital, Edinburgh. DNA
samples were bisulphite converted and hybridised to the
12 sample Illumina HumanMethylation450BeadChips
using the Infinium Methylation protocol and Tecan
robotics.
Extensive quality control was conducted, as reported
in Zhang et al., [21] to leave a dataset consisting 470,278
CpG sites from 436 LBC1921 participant observations.
Briefly, one sample from each duplicate pair (same sam-
ple from the same wave) was removed, along with one
sample from each replicate pair (same sample, different
analysis set). Samples and CpG sites with low call rates
(95% of CpGs and samples with P < 0.01) were excluded,
as were XY probes.
Following this initial screening process, the raw IDAT
files for these 436 individuals underwent a separate
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quality control analysis. This was conducted in accordance
with the recommended analysis procedure in Hovarth’s
epigenetic clock tutorial (https://dnamage.genetics.ucla.
edu/), to help reduce missing CpG values. Raw DNAm
IDAT files were read into R, using minfi, and were nor-
malised using the noob (normal-exponential convolution
using out-of-band probes) method, implemented by the
preprocessNoob() function. This method estimates back-
ground noise from out-of-band probes and removes it for
each individual sample; and performs dye-bias normalisa-
tion whereby a subset of control probes estimate the dye
bias. The getBeta() function of minfi was used to obtain
noob-normalised methylation beta values.
Measures of epigenetic age
The online calculator developed by Hovarth (https://dna
mage.genetics.ucla.edu/) was used to determine measures
of epigenetic age (Intrinsic Epigenetic Age, Extrinsic Epi-
genetic Age, DNAm GrimAge, and DNAm PhenoAge)
from the beta values described above. The age calculator
performed a further normalisation process on the LBC1921
methylation data entered into the algorithm. Age acceler-
ation measures were obtained for PhenoAge and GrimAge
by extracting residuals from the model of epigenetic age on
chronological age.
Intrinsic epigenetic accelerated aging (IEAA), and ex-
trinsic epigenetic accelerated ageing (EEAA) have been
described in detail within the literature by Chen et al. [6]
IEAA is defined as the residual that resulted from a
multivariate regression of epigenetic age – calculated
using the Hovarth epigenetic age measure – on chrono-
logical age and measures of blood cell counts [6]. EEAA
was based on the epigenetic age calculated using the
measure described by Hannum et al., with a weighted
average of Hannum’s age estimate being produced in
order to increase the contribution of certain blood cell
types (known to change with age) on the age estimation
[6]. The resulting age estimate was regressed on chrono-
logical age in a univariate model, with EEAA represent-
ing the resulting residual variation [6].
Additional variables
Covariates included in the main statistical models were as
follows: age, sex, APOE ɛ4 carrier status, ever-smoking
status, history of hypertension, history of diabetes and his-
tory of either cardiovascular or cerebrovascular disease.
Genomic DNA was isolated from participants’ venous
blood in order to determine APOE ɛ4 status. Participants
were classified as carriers if they possessed one or more
APOE ɛ4 alleles. Date of birth, sex, smoking history and
history of hypertension, diabetes, cerebrovascular, and car-
diovascular disease were self-reported by participants at
the first wave of testing. Age was calculated as the number
of days between date of birth and date of attendance at
wave 1 testing. Additional analyses were performed to fur-
ther investigate the component parts of AgeAccelGrim;
additional covariates therefore included the DNAm-based
surrogates for seven proteins and smoking pack years
(beta-2 microglobulin (DNAm B2M), cystatin-C (DNAm
Cystatin C), growth differentiation factor 15 (DNAm
GDF-15), plasma activator-inhibitor 1 (DNAm PAI-1),
Leptin (DNAm Leptin), adrenomedullin (DNAm ADM),
and tissue inhibitor metalloproteinase 1 (DNAm TIMP-1)
and DNAm PACKYRS.
It was important to determine the association between
chronological age and dementia, before exploring whether
DNA methylation-based measures of accelerated aging
could be of greater predictive value in assessing dementia
risk, hence the inclusion of chronological age in the ana-
lyses. Given the narrow-age nature of our cohort, there is
little variance in age and we would not expect to observe a
statistically significant association between age and de-
mentia; the chronological age variable would not therefore
be included in subsequent statistical models if this
assumption was confirmed. APOE ɛ4 carrier status was in-
cluded because of the known association with dementia,
particularly as this association had been replicated in earl-
ier studies of this cohort [22]. Smoking status was intro-
duced given the recognised effect that smoking has on
DNA methylation [23], and the potential for this to affect
the findings. Furthermore, whereas smoking had not been
found to be associated with dementia in previous studies
of this cohort, it has been reported to be an important risk
factor within the literature. A history of hypertension, dia-
betes and cardiovascular or cerebrovascular disease were
included given the potential association with earlier death
and dementia. Furthermore, such health outcomes in-
crease with advancing age and so greater epigenetic age
could be associated with susceptibility to these conditions
[24, 25]. An interaction term for sex and measure of accel-
erated ageing was included as sex is strongly linked to
both AgeAccelPheno and AgeAccelGrim. Whereas other
factors – such as age 11 IQ – could be proposed to be as-
sociated with dementia [26], such variables have not been
shown to be important with regard to dementia risk in
this cohort and were not therefore included [22, 27]. Our
hypothesis-driven approach, based on previous findings
aimed to minimise the inclusion of variables that would
not be relevant in this sample, and reduce the possibility
of multiple hypotheses testing.
Dementia ascertainment
Dementia case ascertainment in LBC1921 has been de-
scribed previously in detail [22]. Briefly, cases were
ascertained retrospectively, up to age 95 years, based on
evidence collected from death certificates, medical re-
cords, and a small number of clinical assessments [22].
Death certificates available by the end of June 2016 were
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examined for any recording of either dementia or cogni-
tive decline, in any position. For each participant who
consented to data linkage and access to records, local
electronic hospital records were reviewed and any evi-
dence for dementia or cognitive decline was collected.
Prior to 2014, psychiatric records were held on a separ-
ate electronic system and diagnoses were supplied to the
study in the form of ICD-9 and ICD-10 codes for those
who had been in contact with psychiatric services. ICD-9
and 10 codes that were relevant to the dementia ascertain-
ment process are shown in Additional file 1: Figure S1.
Latterly, psychiatric records were merged with the general
hospital system and accessed as previously described. Data
for each consenting participants were accessed using their
Community Health Index (CHI) number, a unique identi-
fier specific to each NHS patient in Scotland and recorded
at each contact. The last date for data collection from
medical records was the 16th of May 2016. Additional evi-
dence was available for a small proportion of participants
(n = 26) who underwent clinical review by one of the
authors (TCR, JMS), either in the NHS or research setting.
Any participant who reported a new diagnosis of dementia
at routine LBC1921 follow-up, or any participant for
whom a concern was raised regarding cognitive decline,
was referred for such clinical assessment. Data from such
reviews were collected up to 15th December 2016, when
all of the evidence gathered was reviewed and discussed at
a final dementia diagnosis consensus meeting (RAS, TCR,
JMS). The meeting agreed upon the presence of a diagno-
sis and the subtype, using a previously described list of
criteria for ‘probable’ or ‘possible’ dementia diagnosis [22].
Any disagreement was resolved through discussion. To
minimise the potential for introducing classification error
to the results, possible dementia cases were excluded from
the analyses.
Time-to-event variables
The events included in this study are dementia and
death, determined as described above. The number of
days between the date of attendance at wave 1 testing
and date of death gave the ‘time to death’. For those
who did not die, the censoring time was taken as the
number of days between wave 1 testing and a date be-
yond that last date of data collection for any participant
(6500 days after baseline testing). The number of days
between the date of attendance at wave 1 testing and the
first date that a dementia diagnosis was noted in any of
the available sources gave the ‘time to dementia’. Where
dementia was recorded on a death certificate and no
duration was given, and dementia was not recorded in
another source, the diagnosis was presumed to predate
death by six months. Where the duration was not given,
but a diagnosis was recorded in another source, the
earliest such date was used to determine the date of
onset. If sources recorded both cognitive impairment
and dementia, the date of dementia onset was taken as
the earliest recording of a dementia diagnosis. If demen-
tia diagnosis was determined based on evidence that did
not include a formal diagnosis of dementia, the earliest
mention of cognitive impairment was used to date onset
(as long as the same record did not specifically note the
absence of a dementia syndrome). For participants who
remained dementia-free, the ‘time to dementia’ variable
was taken as either the time to date of death or to a date
beyond that last date of data collection for any surviving
participant (6500 days after baseline testing).
Statistical analysis
The first step in analysing the data was to demonstrate
any statistically significant differences (p < 0.05) between
the group who developed dementia and the group who
did not. Univariate analysis – using either the Pearson
chi-square or t-test (IBM SPSS, Version 21) – was com-
pleted for each variable that would be included in the
main analyses. The same software was used to calculate
the level of correlation between the measures of epigen-
etic age acceleration. R statistical software, (package
‘cmprsk’ in R version 3.5.1) was used to perform all sub-
sequent steps in the analyses.
The main analyses were completed using competing risk
regression (CRR) models, in which death was considered a
competing risk for dementia. Having been considered in a
number of previous studies, the association between age
acceleration measures and death would not be a primary
focus of this study; incident dementia after age 79 years
was the primary outcome to be reported. Death and de-
mentia compete for risk in that they non-independently
occur. This changes the risk function that a given variable
may have with an outcome. For example, older individuals
are likely to both die and get dementia. Two individuals
might both die at the same time, before being diagnosed
with dementia. One of these individuals would have devel-
oped dementia in a few months had they lived, the other
would not have developed dementia for several years. In a
more standard logistic or Cox model predicting only de-
mentia diagnosis, both individuals would be censored out
of the analysis at the time of death, and the information
on the competing risk of death is ignored. Competing risk
regression models take into account the information from
a competing risk and reweights the primary outcome risk
in light of competing outcomes. The first CRR regression
model (CRR 1) explored the association between age and
dementia, with chronological age (at baseline testing)
being the only variable included. Chronological age was
excluded from subsequent models as it did not prove to
be statistically significant in this first model. The second
model (CRR 2) examined measures of accelerated aging as
a marker of biological ageing; the covariates included in
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the model were the given DNA methylation measure of
accelerated ageing, sex, APOE ɛ4 carrier status, and a
DNA methylation age acceleration and sex interaction
term. The interaction term was to be excluded from sub-
sequent models if it did not reach statistical significance.
The third model (CRR 3) included these same variables,
with the addition of ever-smoking status. The final model
(CRR 4) included three additional health outcome vari-
ables – history of hypertension, history of diabetes, and
history of cardiovascular or cerebrovascular disease. Ac-
celerated ageing, sex and APOE ɛ4 are also included in
this model. Smoking status is included if it was statistically
significant in model 3.
The main findings of the CRR analyses were supported
with cumulative incidence plots for each competing
event (dementia and death); these illustrate the time-
varying risk of dementia, between covariate levels. The
Aalen-Johansen estimator was used to calculate the un-
biased estimate of cumulative incidence. In addition to
the CRR models, logistic regression models would be
completed to establish the associations between variables
and dementia, when death outcomes are not considered.




The complete LBC1921 cohort included N = 550 partici-
pants who were recruited and attended baseline testing
at age 79 years. The participants eligible for these ana-
lyses did not include those who had an MMSE score of
less than 24 at baseline (n = 9), those without a valid
MMSE score at baseline (n = 2), those who reported a
history of dementia at baseline (n = 2), and those with
no follow-up data available for the purpose of dementia
ascertainment (n = 41). For one participant, the calcu-
lated time to dementia suggested that dementia predated
attendance at wave 1 testing and they were also excluded
from the study sample. Of those who were eligible for
inclusion in this study (n = 495), a consensus diagnosis
of probable dementia was agreed for n = 109 and a con-
sensus diagnosis of possible dementia was agreed for
n = 7. Those with possible dementia were excluded from
the analyses, resulting in a final study sample of n = 488
participants. Exclusions were made on a step-wise basis
as shown in Fig. 1, with a total of n = 62 participants ex-
cluded from these analyses. Over half of the included
participants were female (57.4%, n = 280) and over
three-quarters were known to be deceased by the 30th
of June 2016 (85.9%, n = 419). Of those who were de-
ceased, 79.0% (n = 331) had died without a diagnosis of
dementia. Descriptive statistics for those included and
excluded are shown in Table 1, alongside group com-
parison statistics for those with and without dementia.
Dementia group comparison
Univariate analyses demonstrated little difference between
those eligible participants who developed dementia and
those who did not. Positive ever-smoking status (p <
0.001), greater smoking pack years (p = 0.016), increased
DNAm GrimAge age acceleration (AgeAccelGrim) (p <
0.001) and increased extrinsic epigenetic accelerated age-
ing (EEAA) (p = 0.047) reduced the risk for dementia,
while positive APOE ɛ4 (p < 0.001) carrier status increased
the risk for dementia.
Time-to-event variables
The mean time to dementia and the mean time to death
for the eligible study sample were 3371.0 (SD: 1724.7)
Fig. 1 Flowchart for participant exclusion process
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days and 3618.9 (SD: 1829.3) days, respectively. The
mean time to death for deceased participants (n = 419)
was 3144.5 days (SD: 1517.5). For the participants who
survived, the ‘time to death’ variable value was taken as
the number of days between baseline testing and a date
beyond the last date of data collection for any partici-
pant; 6500 days. The mean time to dementia for those
who developed dementia (n = 109) was 3535.7 days (SD:
1283.3). For the participants who remained free of de-
mentia (n = 379), ‘time to dementia’ variable value was
taken either as the time to death for those who died
(n = 331, mean = 2863.0 days, SD: 1469.4), or time to a
date beyond the last date of data collection for any par-
ticipant for those who survived (n = 48; 6500 days).
Main analyses
The first competing risk model (CRR 1), included a sin-
gle variable – chronological age (at baseline). In our
study cohort (n = 488), chronological age at baseline did
not demonstrate a statistically significant association
with incident dementia (HR 1.00 [95% CI 1.00, 1.00],
p = 0.61). Chronological age was not, therefore, included
in subsequent competing risks models. The variables in-
cluded in each model are shown in Fig. 2.
Table 1 Study sample demographics and univariate analyses







Dementia (n = 109) No Dementia (n = 379)
Age n = 109 n = 379 n = 62
-mean age in years (SD) 79.04 (0.55) 79.08 (0.59) 0.540 79.09 (0.53)
Sex n = 109 n = 379 n = 62
% female 62.4% 55.9% 0.230 58.1%
Living or deceased n = 109 n = 379 n = 62
% deceased 80.7% 87.3% 0.081 29.0%
MMSE score at baseline n = 109 n = 379 n = 60
mean score (SD) 28.10 (1.64) 28.33 (1.46) 0.156 27.27 (2.67)
APOE ɛ4 carrier status n = 109 n = 373 n = 61
% carrier APOE ɛ4 41.3% 22.5% < 0.001 27.9%
Age 11 IQ (standardised) n = 101 n = 339 n = 53
mean score (SD) 100.19 (16.18) 100.22 (14.53) 0.982 98.21 (15.63)
Smoking status n = 108 n = 379 n = 62
% ever smoker 42.6% 61.7% < 0.001 50.0%
Lifetime smoking packs* n = 108 n = 376 n = 58
mean total packs (SD) 4359.83 (8016.04) 6616.27 (8740.85) 0.016 3880.78 (6609.45)
History of hypertension n = 108 n = 375 n = 61
% positive history 35.2% 41.9% 0.212 41.0%
History of diabetes n = 109 n = 379 n = 62
% positive history 4.6% 5.8% 0.624 1.6%
History of cardiovascular or
cerebrovascular disease
n = 104 n = 373 n = 59
% positive history 28.9% 28.2% 0.889 22%
EEAA n = 88 n = 295 n = 53
mean (SD) 0.37 (7.27) 2.35 (8.41) 0.047 −0.27 (6.68)
IEAA n = 88 n = 295 n = 53
mean (SD) −0.64 (5.60) 0.80 (6.84) 0.074 0.59 (5.13)
AgeAccelGrim n = 88 n = 295 n = 53
mean (SD) −1.30 (4.14) 0.66 (4.64) < 0.001 −0.39 (4.91)
AgeAccelPheno n = 88 n = 295 n = 53
mean (SD) 0.21 (6.56) 1.75 (7.63) 0.087 0.53 (6.55)
Note. *Lifetime smoking packs calculated by number of packs (20 cigarettes) smoked per year multiplied by the number of years smoking
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All subsequent models included a measure of acceler-
ated ageing and each was completed four times – using
EEAA, IEAA, AgeAccelPheno and AgeAccelGrim, in turn,
as the measure of accelerated ageing (CRR models XEEAA,
XIEAA, XAgeAccelPheno and XAgeAccelGrim respectively). The
results for models 2–4 (for each age acceleration measure)
are shown in Table 2. CRR 2 included four covariates:
measure of accelerated ageing, sex, APOE ɛ4 carrier status
and a sex by measure of accelerated ageing interaction
term. In CRR 2AgeAccelGrim, where AgeAccelGrim was used
as the measure of accelerated ageing, greater accelerated
ageing was associated with lower risk of incident dementia
(HR 0.89 (0.81, 0.97), p = 0.009). In the same model, carry-
ing no APOE ɛ4 alleles was associated with a lower risk
for incident dementia (HR 0.45 (0.30, 0.69), p < 0.001). A
relationship between sex and incident dementia was not
demonstrated (HR 0.84 (0.53, 1.34), p = 0.46). Similarly,
the association between the sex by AgeAccelGrim inter-
action term and dementia did not reach statistical signifi-
cance (HR 1.05 (0.94, 1.18), p = 0.38). When model 2 was
repeated, using IEAA, EEAA and AgeAccelPheno (CRR
2IEAA, 2EEAA and 2AgeAccelPheno respectively), the associ-
ation between accelerated ageing and dementia did not
reach statistical significance. APOE ɛ4 negative carrier sta-
tus associated with a lower risk for incident dementia in
each of the three models. CRR 3 included the same covari-
ates as model 2, with the addition of smoking status (ever
smoker versus never smoker). Given its lack of statistical
significance, the sex by age acceleration interaction term
was dropped from subsequent models. In CRR 3AgeAccel-
Grim, the association between accelerated ageing (AgeAc-
celGrim) and dementia no longer reached statistical
significance (HR 0.95 (0.89, 1.01), p = 0.09). Lifelong non-
smoking (never smoking status) was associated with a
higher risk of incident dementia (HR 1.69 (1.06, 2.71), p =
0.03). Negative APOE ɛ4 status continued to be associated
with a lower risk of dementia (HR 0.44 (0.29, 0.67), p <
0.001). In CRR 3IEAA, 3EEAA and 3AgeAccelPheno there was
no statistically significant relationship between accelerated
ageing and dementia. Lifelong non-smoking status was as-
sociated with a higher risk of incident dementia in all
three models; negative APOE ɛ4 carrier status was again
associated with a lower risk of incident dementia in the
three models. In CRR 4AgeAccelGrim – which included his-
tory of hypertension, diabetes, cardiovascular or cerebro-
vascular disease as covariates – only APOE ɛ4 carrier
status (HR 0.41 (0.27, 0.64), p < 0.001) and smoking
status (HR 1.69 (1.05, 2.73), p = 0.03) reached statis-
tical significance, with negative APOE ɛ4 carrier
status reducing risk for incident dementia and never-
smoking status increasing the risk for incident demen-
tia. The same two variables reached statistical significance
for the models including EEAA, IEAA and AgeAccel-
Pheno as measures of accelerated ageing.
Fig. 2 Competing Risk Regression Models. α Each model was repeated four times, each time substituting a different DNA methylation-based
measure of accelerated ageing: EEAA, IEAA, AgeAccelPheno, AgeAccelGrim
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Each model was repeated as a logistic regression model,
with probable dementia as the outcome. In these analyses
– where death was not considered – the association be-
tween AgeAccelGrim and dementia reached statistical sig-
nificance in models 2 and 3 (p < 0.05) and approached
significance in model 4 (p = 0.06). In each case, greater
age acceleration reduced the risk for subsequent dementia.
The association between AgeAccelPheno, EEAA, IEAA
and dementia was not statistically significant in any model.
Being a non-carrier for the APOE ε4 allele was associated
with a reduced risk for dementia in every model (p <
0.001). Being a never-smoker increased the risk for de-
mentia in every model where it was included (p < 0.05).
The complete results for the logistic regression are avail-
able in Additional file 2: Table S1.
Components of AgeAccelGrim
Given that the association observed between AgeAccel-
Grim and dementia was the only significant finding regard-
ing the age acceleration measures when examined using
competing risk regression analyses (CRR 2AgeAccelGrim), and
that the direction of association was opposite to what we
might have expected, we wished to investigate it further.
Based on the change in statistical significance observed
following the introduction of a smoking variable, we hy-
pothesized that the association seen had been related to
the smoking component of the age acceleration measure.
By separating out the individual components of AgeAccel-
Grim, we were able to look at the association between the
DNA methylation-based surrogate biomarker for smoking
pack years and dementia on its own to see if any associ-
ation we were seeing for the measure overall was mirrored
in what was observed for this component. The components
on which the AgeAccelGrim measure was based were
therefore considered in turn. Model 2 was repeated
eight times, each time substituting a component of the
measure for AgeAccelGrim. The components included
DNA methylation-based surrogate markers for smoking
pack years (DNAm PACKYRS) and seven plasma proteins
– beta-2 microglobulin (DNAm B2M), cystatin-C (DNAm
Cystatin C), growth differentiation factor 15 (DNAm GDF-
15), plasma activator-inhibitor 1 (DNAm PAI-1), Leptin
(DNAm Leptin), adrenomedullin (DNAm ADM), and tis-
sue inhibitor metalloproteinase 1 (DNAm TIMP-1). Each
was entered into a competing risk regression model along
with APOE ɛ4 carrier status and sex. An interaction term
was not included given that it was not previously found to
be statistically significant. Only the association between the
DNAm PACKYRS component and dementia reached stat-
istical significance (HR: 0.97 [0.95, 0.99], p = 0.007). The
complete results for these component analyses are provided
in Additional file 3: Table S2.
These analyses were again repeated as logistic regression
analyses. The association between DNAm PACKYRS and
dementia once again reached statistical significance (p <
0.05). The complete results for these analyses are provided
in Additional file 4: Table S3.
Cumulative incidence graphs
Figure 3 shows cumulative incidence plots for the two
competing events: dementia and death. The general direc-
tion of the cumulative incidence plot does seem to sup-
port the direction of the association observed between
AgeAccelGrim and dementia in CRR 1AgeAccelGrim, with
increased risk for dementia for those with lower levels of
age acceleration. Based on the figure, it would appear that
the reversal and divergence of the association between age
acceleration and dementia begins 10 years after baseline,
when subjects are aged approximately 89 years. In contrast
with the unclear pattern demonstrated for dementia, the
cumulative incidence plot indicated a greater risk for
death for those with highest levels of accelerated ageing
(calculated using AgeAccelGrim in our study) compared
with those with lowest levels of age acceleration. This re-
sult reinforced the patterns of association shown in previ-
ous studies, where higher age acceleration was associated
with a greater risk of mortality [7].
Correlation between measures of age acceleration
In this study cohort, positive correlations were shown be-
tween each of the four measures of epigenetic age acceler-
ation (0.259 ≤ r ≤ 0.439) (Additional file 5: Table S4). The
strongest correlation was seen between EEAA and AgeAc-
celGrim (r = 0.439), but this was only marginally greater
than the correlations observed between EEAA and AgeAc-
celPheno (r = 0.424), AgeAccelPheno and AgeAccelGrim
(r = 0.416) and AgeAccelPheno and IEAA (r = 0.403). The
weakest correlation was seen between IEAA and AgeAccel-
Grim (r = 0.259); this may reflect the fact that IEAA is
based on Horvath’s original measure which was developed
using multiple tissue types, while AgeAccelGrim was devel-
oped using blood methylation data alone [12].
Discussion
This study aimed to determine whether DNA methylation-
based measures of accelerated ageing were associated with
risk for dementia in the oldest-old. The results did not dem-
onstrate any consistent relationship between DNA-based
measures of accelerated ageing and incident dementia. The
initial findings suggested that increased AgeAccelGrim may
be associated with decreased risk for incident dementia in
those aged over 79 years. However, on subsequent test-
ing the results indicated that smoking might explain
this association, and more specifically, that it was likely
to be the collinear relationship between GrimAge and
smoking that had given rise to this finding.
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Comparison with previous findings
Whereas a number of studies have suggested an increased
risk for dementia associated with DNA methylation pat-
terns at specific loci or with increased DNA methylation
age, we are not aware of any studies that specifically exam-
ined the relationship between methylation-based measures
of accelerated ageing and dementia [28–31]. For this rea-
son, it is not possible for us to directly compare our find-
ings. We can however consider previous notable findings
relating DNA methylation and dementia.
Investigating how a change in the expression of DNA
alters the risk of developing the dementia is of clear
value in both furthering our understanding of the patho-
genesis of the disease and in guiding the development of
effective treatments. To this end, several studies have
considered how specific changes in DNA methylation
affect one’s risk of developing dementia, with notable
epigenetic changes being observed between subjects with
dementia and controls [30]. Recent studies have indi-
cated that DNA methylation may indeed contribute to
the pathogenesis of dementia. For example, the APOE
gene (variants of which are recognised to be important
in dementia risk) has been shown to be differently meth-
ylated in Alzheimer’s disease (AD) [32]. Specifically,
reduced methylation levels at a well-defined CpG island
within the fourth exon of the APOE gene in brain tissue
were observed in AD subjects when compared with
controls; these differences in methylation levels were ob-
served in both the hippocampus and frontal lobe regions
of the brain, where AD pathophysiological changes were
abundant [32]. Furthermore, DNA methylation levels
were increased in the presence of an APOE ɛ4 allele in
controls, but not in AD subjects [32]. Studies have also
reported changes in DNA methylation, in relation to
AD, at several other genes [30]. In 2014, De Jager et al.
and Lunnon et al. published the results of two large-
scale epigenome-wide association studies (EWAS) in
Alzheimer’s disease [33–35]. Differences in methylation
were reported at a number of loci, including four that
were independently identified in both studies: ANK1,
RPL13, C10orf54-CDH23 and RHBDF2 [33–35]. A 2016
systematic review by Wen et al. described studies report-
ing higher methylation levels of several genes (observed
in peripheral blood cells or brain tissue of AD patients)
Fig. 3 Cumulative incidence plots for AgeAccelGrim: death and dementia. Note. The two groups for each event (death and dementia) were
formed from the half of participants with higher age acceleration levels who experienced that event and the half with lower age acceleration
levels that experienced that same event. A steeper rising line indicates that individuals in this group were at greatest risk for the event, e.g., in
general, individuals were more at risk for death than dementia
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including OPRK1, BDNF, UQCRC1, HTERT, TREM2,
TBX2AR, SORBS3, SPTBN4, and CREB promotors and the
synaptophysin gene [30]. Lower levels of methylation of a
number of other genes were reported in the blood or brain
tissues of AD subjects, including PIN1, FAAH, ALOX5,
DR4, TNFA, COX-2, NF-kβ, CRTC1 and S100A2 [30].
Other studies have also suggested differences in global
DNA methylation – i.e. the overall level of methylcytosine
within the genome – between AD subjects and controls
[30]. While the results described are not consistent across
all studies, the evidence would seem to support the hypoth-
esis that DNA methylation plays an important role in
dementia.
Findings relating to DNAm age and dementia are of
particular relevance here given the direct relationship
between DNA methylation-based age and measures of
accelerated ageing. Levine at al. (2018) tested for an
association between pathologically determined AD and
DNAm PhenoAge in the dorsolateral prefrontal cortex
[11]. They found that when comparing same-age indi-
viduals, the dorsolateral prefrontal cortex appeared more
than one year older in those with AD [11]. Furthermore,
DNAm PhenoAge was associated with typical neuropatho-
logical signs of AD including neurofibrillary tangles, amyl-
oid load and neuritic plaques [11]. A previous Swedish
longitudinal study examined the association between
DNAm age (calculated using Hovarth’s epigenetic clock)
and dementia and the authors reported that increased
DNAm age was a statistically significant predictor for de-
mentia (β = 0.16, p = 0.019) [28]. This was however a small
study, with n = 11 dementia cases, and the logistic regres-
sion analyses were adjusted for gender only [28]. DNAm
age was calculated at a time when n = 6 of these cases were
already diagnosed, and n = 5 were diagnosed in the follow-
ing four years [28]. We must therefore consider whether
this study describes an association between advanced
DNAm age in existing dementia, as opposed to increased
DNAm age predicting dementia.
Based on these previous findings, one might have ex-
pected that the present study would have identified a
similar association between accelerated ageing and de-
mentia. There may be a number of reasons why this was
not the case, and these are discussed within the context
of the mechanisms and limitations of the study below.
Mechanisms
Whereas chronological age is widely recognised to be
associated with dementia, this was not the case in our
study cohort. It is probable that the absence of such an
association in this study can be attributed to the use of a
narrow-age cohort. In studies of methylation age and de-
mentia using participants of a wider age-range, chrono-
logical age would likely be an important covariate for
inclusion. As has been shown previously in this study
cohort [22, 27], the presence of at least one APOE ɛ4
allele was related to an increased risk of incident demen-
tia. As such, it remains an important covariate for inclu-
sion in studies of dementia in those aged over 80 years.
The results of the analyses included in this study did
not find any consistent relationship between DNA-based
measures of accelerated ageing and incident dementia.
Only one model yielded a result for accelerated ageing
that reached statistical significance at conventional
levels. Indeed, this result contradicted the hypothesised
results, with increased accelerated ageing (AgeAccel-
Grim) being associated with a reduced risk for incident
dementia. This finding would contradict those previous
studies that have shown an association between in-
creased methylation age and greater risk for developing
age-related health outcomes [6, 7]. Given the unexpected
direction of this association, one must consider the ro-
bustness of this finding. Given that the magnitude of the
association was relatively small and was not observed in
any subsequent model it may be that this was a chance
finding that does not demonstrate a true association. In
this study, the introduction of a smoking variable meant
that the association between AgeAccelGrim and demen-
tia no longer reached statistical significance. Such a find-
ing might be expected given that GrimAge is built, in
part, on smoking related data and the two are extremely
collinear, correlating at approximately 0.9. We note that
the direction of association between smoking and dementia
in this study is the same as that for AgeAccelGrim and de-
mentia. We therefore suggest that an association between
smoking and dementia seems to explain the observed rela-
tionship between AgeAccelGrim and dementia. Our finding
that the DNA methylation-based marker for smoking pack
years was the only component of AgeAccelGrim associated
with dementia in this cohort provided further evidence for
this explanation.
In these analyses, a lifelong history of non-smoking was
associated with an increased risk for dementia. While the
direction of this association may defy the expected and
contradict previous studies, it is in line with a general pat-
tern observed in this cohort of individuals aged over 79
years [22]. A previous study of the LBC1921 has also dem-
onstrated an increased risk for dementia after age 79 years
with greater lifetime physical activity, and a decreased risk
for dementia for those with a history of hypertension at
age 79 years [22]. Similarly, other factors that have previ-
ously been shown to increase risk for dementia in studies
of earlier old age have been found to have no effect on risk
in this cohort of participants aged over 79 years [22, 27].
In a previous study of physical fitness and dementia in the
LBC1921, a positive history of ever-smoking was observed
to decrease risk for dementia, but in that study the associ-
ation did not reach statistical significance [27]. It would
therefore appear that the statistical significance of the
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association between ever-smoking and dementia within our
cohort is dependent on the covariates included in the ana-
lyses. It is possible that the direction of the association be-
tween age acceleration and dementia observed in these
analyses simply reflects of the direction of the association be-
tween smoking and dementia in this this cohort, but we ac-
knowledge that the inconsistency in statistical significance
means that we must treat the association observed in this
study with caution. We must also consider whether survival
to age 79 years or recruitment at age 79 years have influ-
enced our smoking-related findings. It is possible that those
individuals who were most likely to have experienced greater
risk for dementia as a result of previous or current smoking
had died earlier to age 79 years, leaving only those who
would remain unaffected or in some way ‘resistant’ to the
negative effects of smoking. Similarly, we must consider the
possibility that those who would have been more likely to de-
velop dementia a result of their smoking history had done so
prior to recruitment age and would not therefore have been
eligible to enrol in the LBC1921 study. Given that suscepti-
bility for lung disease is variable between persons [36], one
might suggest that there is a similar variability in susceptibil-
ity for dementia and those who remained dementia free at
age 79 would be those with a reduced susceptibility, giving
rise to an apparent reduction in risk for smokers.
Implications
Without any consistent results it is difficult to draw any
comparisons between the age acceleration measures
considered in this study, and how useful each might be in
establishing risk for incident dementia. Furthermore, the
lack of positive findings regarding dementia in the present
study limits the clinical implications specific to dementia.
There is a clear requirement for further study in this field; a
full appreciation of the role of DNA methylation and DNA
methylation-based measures of accelerated ageing in de-
mentia could be of considerable value in furthering our
understanding of the risks for dementia and identifying po-
tential targets for risk reduction. Our null finding might ini-
tially suggest that future similar studies were not required.
Given some of the limitations of our study cohort however,
we cannot assume that our study answers this research
question conclusively, particularly given that this has not
been investigated previously within the literature. Our sug-
gestion for larger studies would be to overcome the poten-
tial limitations of our study that may have given rise to the
null finding. A stand-alone study can rarely be taken as
conclusive evidence and additional studies would therefore
either add strength to, or refute, our null finding.
Strengths and limitations
The study cohort used in these analyses has a number of
strengths. The LBC1921 is a narrow-age cohort of persons
aged 79 years of age at baseline; this means that the study
does not suffer from the major confounding effect of
chronological age. As such, the cohort is suited to the
study of dementia in the oldest-old. Given the homoge-
neous nature of the cohort participants, confounding er-
rors resulting from age, ethnic, cultural and geographical
variability would be unlikely. Participants have taken part
in a detailed longitudinal follow-up procedure, and death
ascertainment for the cohort is complete. Previously pub-
lished assessments of validation have shown the dementia
ascertainment methods used in this study to be effective
and incidence rates to be comparable with expected rates
for the cohort [22]. We cannot however exclude the possi-
bility of missed or misclassified cases of dementia in our
cohort. In particular, a limitation of our study is the
potential that we missed cases of preclinical or prodromal
dementia in participants who died prior to developing
clinical dementia. In addition to this, it is possible that
cases of preclinical or prodromal dementia present at the
time we concluded our ascertainment would have gone
on to develop dementia after that date.
The indication of a possible reverse association (to
that which was expected) for AgeAccelGrim, combined
with the surprising association with never smoking (in
addition to those unusual associations observed in pre-
vious manuscripts), could suggest a cohort effect; it is
possible that something specific about this study sam-
ple – such as a survivor bias, or something else about
the nature of recruitment – may have influenced the
results.
A p value of 0.05 was used to determine significance
for all models. We did not therefore specifically compen-
sate for potential erroneous inferences arising from mul-
tiple testing.
Whereas the LBC1921 is a detailed cohort, it is however
limited in size. Studies of DNA methylation-based mea-
sures of accelerated ageing and dementia within larger co-
horts are required to provide further evidence in this field.
As noted above, there were insufficient numbers of eligible
study subjects to further investigate whether DNA methy-
lation age mediates the risk of smoking. This study cohort
did not have a sufficient number of confirmed cases of
dementia of the Alzheimer’s type to allow for a specific
analysis of this outcome. Again, larger studies with sub-
jects who had confirmed dementia aetiology would allow
for such analyses.
Another strength of this study was the inclusion of
death as a competing risk. We hypothesised that death
could affect the results, given the recognised association
between age acceleration and mortality. When we repeat
model 2AgeAccelGrim as a simple Cox regression analysis
(without death as a competing risk), the effect size for
AgeAccelGrim was reduced and did not reach statistical
significance (HR 0.99 (0.93, 1.06)).
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In order to complete our study using a competing
risks type analyses, it was necessary to have ‘time to
event’ variables, including a ‘time to dementia’ for those
who developed the condition during the follow-up
period. We have described within the methods the man-
ner by which such estimates were determined for these
analyses. We must however recognise the uncertainty
that exists regarding the accuracy of this estimate. The
nature of dementia and the often gradual onset mean
that it is difficult to pin-point an exact date of onset.
Furthermore, the variability in how each individual per-
ceives their own symptoms and the differing stages at
which one may present for cognitive assessment mean
that when diagnoses are ascertained from records, time
of onset may be even harder to determine. Depending
on the source of data available for dementia ascertain-
ment, the date of diagnosis was not always listed, making
it even more difficult to calculate a time to dementia
estimate. In this study, the methods for calculating the
time to dementia aimed to provide the most accurate
estimate that was possible using the available informa-
tion, but the potential for inaccurate estimates to have
affected the results is acknowledged.
Finally, while we must consider the potential for in-
accuracy in self-reported smoking data. This is however
less relevant in this study given the accuracy of the DNA
methylation based marker for smoking.
Conclusion
In conclusion, the present study did not demonstrate
any consistent association between DNA methylation-
based measures of accelerated ageing and dementia in
subjects aged over 79 years. Further, larger studies – in-
cluding analyses of separate dementia subtypes – are re-
quired to further investigate the potential association
between DNA methylation-based measures of acceler-
ated ageing and dementia.
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